Sai Prasad, Executive Director, Bharat Biotech International Limited (BBIL), said Phase I data for neutralising antibodies has shown good immunogenicity.from Top India News- News18.com https://ift.tt/2GrOFrS
via IFTTT
Tuesday, 3 November 2020
Covid-19 Vaccine: Bharat Biotech Says No Major Adverse Effects in Two Phases of Covaxin Trials
Sai Prasad, Executive Director, Bharat Biotech International Limited (BBIL), said Phase I data for neutralising antibodies has shown good immunogenicity.from Top India News- News18.com https://ift.tt/2GrOFrS
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment